



microRNAs in Colorectal Cancer

Guest Editors:

Dr. Ion Cristobal

Cancer Unit for Research on
Novel Therapeutic Targets,
Oncohealth Institute, IIS-
Fundación Jiménez Díaz-UAM, E-
28040 Madrid, Spain

Dr. Cristina Carames

1. Cancer Unit for Research on
Novel Therapeutic Targets,
Oncohealth Institute, IIS-
Fundación Jiménez Díaz-UAM, E-
28040 Madrid, Spain
2. Medical Oncology Department,
University Hospital "Fundación
Jiménez Díaz", UAM, E-28040
Madrid, Spain

Deadline for manuscript
submissions:

closed (1 May 2021)

Message from the Guest Editors

Dear Colleagues,

Colorectal cancer is the gastrointestinal cancer with the highest incidence and a major cause of cancer-related death worldwide. It is a heterogeneous disease characterized by a progressive accumulation of genetic and epigenetic alterations that drive tumor progression. The subgroup of patients with distant metastases at diagnosis and those who progress to metastatic disease represent a therapeutic challenge due to their very poor outcome. It has been well demonstrated that microRNAs play key regulatory roles in colorectal cancer, emerging as novel biomarkers and promising molecular targets in this disease. However, their clinical and therapeutic impact needs to be further established before their future inclusion in clinical protocols.

This Special Issue will illustrate the clinical and therapeutic significance of microRNA deregulation in colorectal cancer and their crucial contribution to metastatic progression. We welcome works that provide significant advances in this field with a clear translational impact and novelty.

Dr. Ion Cristobal
Dr. Cristina Carames
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)